about
Dietary Flavones as Dual Inhibitors of DNA Methyltransferases and Histone MethyltransferasesSensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibitionScreening for Small-Molecule Modulators of Long Noncoding RNA-Protein Interactions Using AlphaScreen.An integrative pan-cancer-wide analysis of epigenetic enzymes reveals universal patterns of epigenomic deregulation in cancerInhibition of histone methyltransferase EZH2 ameliorates early acute renal allograft rejection in ratsEZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cellsHedgehog Signaling Overcomes an EZH2-Dependent Epigenetic Barrier to Promote Cholangiocyte Expansion.Squamous Cell Cancers: A Unified Perspective on Biology and GeneticsEpigenetics of oropharyngeal squamous cell carcinoma: opportunities for novel chemotherapeutic targets.n-Butylidenephthalide Regulated Tumor Stem Cell Genes EZH2/AXL and Reduced Its Migration and Invasion in Glioblastoma.Blocking EZH2 methylation transferase activity by GSK126 decreases stem cell-like myeloma cells.SWIM: a computational tool to unveiling crucial nodes in complex biological networks.Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical reviewMechanisms of neuroblastoma regressionMedulloblastoma development: tumor biology informs treatment decisionsThe application of next-generation sequencing-based molecular diagnostics in endometrial stromal sarcoma.Mining the epigenetic landscape of tissue polarity in search of new targets for cancer therapy.Investigation of EZH2 pathways for novel epigenetic treatment strategies in oropharyngeal cancer.H3K36 methyltransferases as cancer drug targets: rationale and perspectives for inhibitor developmentAnticancer Natural Compounds as Epigenetic Modulators of Gene ExpressionOrchestration of H3K27 methylation: mechanisms and therapeutic implication.EZH2 phosphorylation regulates Tat-induced HIV-1 transactivation via ROS/Akt signaling pathway.Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histone demethylation.PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome.The transformation of the nuclear nanoarchitecture in human field carcinogenesis.EZH2-mediated repression of Dkk1 promotes hepatic stellate cell activation and hepatic fibrosis.SETD1A induced miRNA network suppresses the p53 gene expression module.The role of enhancer of zeste homologue 2 inhibitors in controlling epigenetics and their potential for cancer treatment.Construction of a 26‑feature gene support vector machine classifier for smoking and non‑smoking lung adenocarcinoma sample classification.Tetracycline-controllable artificial microRNA-HOTAIR + EZH2 suppressed the progression of bladder cancer cells.Epigenetic regulation of HIV-1 latency: focus on polycomb group (PcG) proteins.Spontaneous regression of neuroblastoma.Interference with endogenous EZH2 reverses the chemotherapy drug resistance in cervical cancer cells partly by up-regulating Dicer expression.Migration/Invasion of Malignant Gliomas and Implications for Therapeutic Treatment.
P2860
Q28554315-D5D4C767-F907-480B-9F77-E8DDD1DDD884Q28829718-A0B2DA09-1319-438C-BBF8-11A4AA083BC7Q35691182-A270927A-3B86-4EBA-82ED-6487006F5C6EQ35848254-2FCEBDE1-76A3-47D2-BE96-6D7802013553Q36175311-EA388710-B0BF-4982-8550-9DDFE762F814Q36212878-EEF1413E-38EB-4F20-A22D-3349F71E77D8Q36218507-2DB1210D-315F-459B-B6AB-1F0E8A0530ACQ36909843-71E0E797-A090-4017-A6B2-16059E604969Q37615798-E0C72C02-90C3-4DA3-8927-3F617A18FB96Q37690899-07998BD4-6A32-46B6-ACA7-6E7D3D8556DDQ37709478-39A84015-78DB-49C9-BB6E-B227A996F809Q37710898-59AEF49F-5105-4863-91DF-F3A93312B47FQ37724905-51C68D29-4039-4F3E-BF1E-92FA248538D0Q38261519-7DAA3BC8-9BBE-42F3-A7FF-88D63C0C5F1BQ38376606-41C12540-3D3C-4ABE-8A50-6B78B166652DQ38381564-B92D8907-96CC-498B-9B15-219CC9D19EEEQ38662513-CD25CFB3-ABD2-4928-9D01-4A18183A7E06Q38735583-E2687D86-5759-4AE7-8359-F90465C2F0A4Q38829055-59C6AF65-C29A-48C4-B503-8BC01198AA17Q39214234-B3B0C055-ECEE-4F27-B625-CF0D08122748Q39440781-2A29EA38-B10B-4B4F-B44D-9229030CE788Q41077207-2AB33F3B-70EB-4311-9104-C1AF8F1DA6E7Q41183886-D5A21032-15AA-4509-8F0F-F5E6ED3EE5A8Q41526004-F3CA24DE-33DA-4FB3-AB40-3F15E0A45F15Q41609288-C4E26016-F02E-42CE-956D-85BE39EAFA59Q42365783-8A7FD33D-4825-4C02-9F0E-BA855553D694Q42385628-C3170AD1-176A-4775-B1CD-32E8A00834B6Q43148207-54F3E118-4CF4-4075-9B1C-E7221AF59026Q47173515-AAAF2FC7-C07B-47F6-A51C-BE9C5F28C359Q48186262-1EA37781-B156-408C-8257-52337E0478B3Q50022535-77CF4519-867E-4A67-8BA9-9CB92EBBE663Q50156376-687A4C41-19B4-4815-8983-F87F026AC15FQ50954236-EC8644A0-0E6C-4C5D-B415-05540AC1B67EQ52593633-4F09D7D9-ACB2-4116-9C75-CF7CB064CD81
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
EZH2 as a potential target in cancer therapy.
@ast
EZH2 as a potential target in cancer therapy.
@en
type
label
EZH2 as a potential target in cancer therapy.
@ast
EZH2 as a potential target in cancer therapy.
@en
prefLabel
EZH2 as a potential target in cancer therapy.
@ast
EZH2 as a potential target in cancer therapy.
@en
P2860
P356
P1433
P1476
EZH2 as a potential target in cancer therapy.
@en
P2093
Caretha L Creasy
Michael T McCabe
P2860
P304
P356
10.2217/EPI.14.23
P577
2014-06-01T00:00:00Z